PART 01: Executive summary
- Highlights
PART 02: Scope of the report
- Market overview
- Top-vendor offerings
PART 03: Market research methodology
- Research methodology
- Economic indicators
PART 04: Introduction
- Key market highlights
PART 05: Erythropoietin: An overview
- Clinical uses of EPO
- Abusive uses of EPO
- Risks of EPO use
PART 06: Global erythropoietin market
PART 07: China: Country snapshot
- Social and economic conditions
- Healthcare reforms
- Healthcare infrastructure
PART 08: Opportunities for pharmaceutical vendors in China
- Major pharmaceutical vendors in China
- Opportunities for global and local vendors
PART 09: Biopharmaceutical market in China
- Biosimilar market in China
- Market size and forecast
PART 10: Market landscape
- Market overview
- Market size and forecast
- Five forces analysis
PART 11: Market segmentation by end-user
- Hospitals
- Retail pharmacies
PART 12: Market segmentation by application
- ESRD
- Cancer
- HIV
- Wounds and neural disease
PART 13: Drug pricing and reimbursement in China
- Market-driven drug pricing strategy
- Scrutinization of illegal pricing of drugs
PART 14: Pipeline portfolio
- NuPIAO
- Uni-EPO-Fc
- PEG-EPO
PART 15: Market drivers
- Increase in CKD and dialysis patient population
- Growth in prevalence of cancer
- Support for local manufacturers
PART 16: Impact of drivers
PART 17: Market challenges
- Complex regulatory framework and approval process
- Complex manufacturing process
- Development of alternative therapies
PART 18: Impact of drivers and challenges
PART 19: Market trends
- Penetration of rhEPO drugs in grade I and II hospitals
- Exploitation of novel therapeutic areas
- Initiation of R&D activities by local/domestic vendors
PART 20: Vendor landscape
- Competitive scenario
- Market analysis 2015
- 3S Bio
- Shanghai Chemo
- Chengdu Di'ao
- NCPC Genetech
- Kyowa Hakko Kirin
- Shandong Kexing
- Other prominent vendors
PART 21: Appendix
- List of abbreviations
PART 22: Explore Technavio

List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Historical timeline of EPO development
Exhibit 03: Globally approved EPO biosimilars
Exhibit 04: China GDP 2010-2014 ($ trillions)
Exhibit 05: China: Healthcare expenditure 2009-2013 (% of GDP)
Exhibit 06: Healthcare reforms in China
Exhibit 07: China pharmaceutical market overview: SWOT analysis
Exhibit 08: New drug approval (NDA) review process in China
Exhibit 09: New drug approval process in China
Exhibit 10: Drug registration classification and requirements in China
Exhibit 11: Notable achievements in biopharmaceutical industry in china
Exhibit 12: Biopharmaceutical market in China 2015-2020 ($ billions)
Exhibit 13: rhEPO market in China in global biopharmaceutical market 2015
Exhibit 14: rhEPO market in China 2015-2020 ($ millions)
Exhibit 15: Five forces analysis
Exhibit 16: rhEPO market in China by distribution channels 2015
Exhibit 17: Share of domestic rhEPO drugs in hospitals in China 2015
Exhibit 18: Changes in the drug pricing system before and after 2015 reforms
Exhibit 19: Pipeline portfolio: rhEPO market in China
Exhibit 20: Impact of drivers
Exhibit 21: Impact of drivers and challenges
Exhibit 22:S Bio: YoY revenue comparison of EPIAO 2014-2015 ($ millions)
Exhibit 23:SBio: Key takeaways
Exhibit 24: Shanghai Fosun: YoY revenue and growth rate of blood system products 2013-2015 ($ millions)
Exhibit 25: Shanghai Chemo: Key takeaways
Exhibit 26: Chengdu Di'ao: Key takeaways
Exhibit 27: NCPC Genetech Biotechnology: Key takeaways
Exhibit 28: Kyowa Hakko Kirin: Key takeaways
Exhibit 29: Shandong Kexing: Key takeaways